NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening The Door To Redosing
Portfolio Pulse from Happy Mohamed
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) has presented preclinical data showing that its Stealth Editors are non-immunogenic, which allows for successful redosing in non-human primates without triggering an immune response. The company expects to present additional data on the gene editing capabilities of Stealth Editors throughout the remainder of 2023.
June 29, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuBase Therapeutics' preclinical data on non-immunogenic Stealth Editors could potentially boost the company's stock in the short term.
The successful preclinical data on NeuBase's Stealth Editors, which are non-immunogenic and allow for successful redosing, could potentially attract more investors, leading to a short-term increase in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100